Opinion|Videos|January 27, 2025
Improving Outcomes Through Patient Education and Addressing Unmet Needs
Panelists discuss how comprehensive patient education about tardive dyskinesia risk factors, early warning signs, and available treatments is crucial for improving outcomes, while highlighting remaining unmet needs including better screening tools, enhanced provider training, expanded access to VMAT2 inhibitors, and more research into prevention strategies and novel therapeutic approaches.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- What role does patient education and awareness play in improving outcomes for those at risk for or living with TD?
- What unmet needs remain in the care of patients with TD, and how can further research or collaboration address these gaps?
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
The all-oral combination is supported by phase 3 LITESPARK-011 data showing improved progression-free survival compared with cabozantinib.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Building a BCMA Bispecific Around the Patient Experience, Not Just the Molecule
5